Athira Pharma logo

Athira Pharma

athira.com

Athira Pharma develops novel small molecule therapies for diseases with limited treatment options, including metastatic breast cancer and ALS. Its lead drug candidates are lasofoxifene and brelgometon (ATH-1105), which are evaluated in clinical trials to improve care for patients through innovative research and product development.

Facts

HQ
Seattle
Sectors
Biopharmaceuticals, Biotech, Pharmaceuticals
Employees
30
Stage
Series B

Is this your organization? Claim it

Members see Athira Pharma's funding rounds, amounts and investors.

People

  • Rachel Lenington Executive, Chief Operating Officer and Chief Development Officer

Online